Advertisement

Meta-Analysis on Risk of Bleeding With Apixaban in Patients With Renal Impairment

Published:November 13, 2014DOI:https://doi.org/10.1016/j.amjcard.2014.10.042
      Apixaban is a novel oral anticoagulant which is approved for the management of atrial fibrillation and venous thromboembolism prophylaxis. There have been concerns regarding bleeding risks with apixaban in patients with renal impairment. We performed a systematic review and meta-analysis to evaluate the risk of bleeding with apixaban in these patients. Relevant studies were identified through electronic literature searches of MEDLINE, EMBASE, Cochrane library, and clinicaltrials.gov (from inception to February 24, 2014). Phase III randomized controlled trials that compared apixaban with conventional agents (vitamin K antagonist and/or warfarin, low molecular weight heparin, aspirin, and placebo) were included. We defined mild renal impairment as creatinine clearance of 50 to 80 ml/min and moderate to severe renal impairment as creatinine clearance <50 ml/min. Study-specific risk ratios were calculated, and between-study heterogeneity was assessed using the I2 statistics. In 6 trials involving 40,145 patients, the risk of bleeding with apixaban in patients with mild renal impairment was significantly less (risk ratio 0.80, 95% confidence interval 0.66 to 0.96, I2 = 13%) compared with conventional anticoagulants. In patients with moderate to severe renal impairment, the risk of bleeding with was found to be similar (risk ratio 1.01, 95% confidence interval 0.49 to 2.10, I2 = 72%). In conclusion, compared with the conventional agents, bleeding risk with apixaban in patients with mild and moderate to severe renal insufficiency is lower and similar, respectively.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lassen M.R.
        • Raskob G.E.
        • Gallus A.
        • Pineo G.
        • Chen D.
        • Hornick P.
        Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
        The Lancet. 2010; 375: 807-815
        • Lassen M.R.
        • Gallus A.
        • Raskob G.E.
        • Pineo G.
        • Chen D.
        • Ramirez L.M.
        Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.
        N Engl J Med. 2010; 363: 2487-2498
        • Granger C.B.
        • Alexander J.H.
        • McMurray J.J.V.
        • Lopes R.D.
        • Hylek E.M.
        • Hanna M.
        • Al-Khalidi H.R.
        • Ansell J.
        • Atar D.
        • Avezum A.
        • Bahit M.C.
        • Diaz R.
        • Easton J.D.
        • Ezekowitz J.A.
        • Flaker G.
        • Garcia D.
        • Geraldes M.
        • Gersh B.J.
        • Golitsyn S.
        • Goto S.
        • Hermosillo A.G.
        • Hohnloser S.H.
        • Horowitz J.
        • Mohan P.
        • Jansky P.
        • Lewis B.S.
        • Lopez-Sendon J.L.
        • Pais P.
        • Parkhomenko A.
        • Verheugt F.W.A.
        • Zhu J.
        • Wallentin L.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Connolly S.J.
        • Eikelboom J.
        • Joyner C.
        • Diener H.-C.
        • Hart R.
        • Golitsyn S.
        • Flaker G.
        • Avezum A.
        • Hohnloser S.H.
        • Diaz R.
        • Talajic M.
        • Zhu J.
        • Pais P.
        • Budaj A.
        • Parkhomenko A.
        • Jansky P.
        • Commerford P.
        • Tan R.S.
        • Sim K.-H.
        • Lewis B.S.
        • Van Mieghem W.
        • Lip G.Y.H.
        • Kim J.H.
        • Lanas-Zanetti F.
        • Gonzalez-Hermosillo A.
        • Dans A.L.
        • Munawar M.
        • O’Donnell M.
        • Lawrence J.
        • Lewis G.
        • Afzal R.
        • Yusuf S.
        Apixaban in patients with atrial fibrillation.
        N Engl J Med. 2011; 364: 806-817
        • Agnelli G.
        • Buller H.R.
        • Cohen A.
        • Curto M.
        • Gallus A.S.
        • Johnson M.
        • Porcari A.
        • Raskob G.E.
        • Weitz J.I.
        Apixaban for extended treatment of venous thromboembolism.
        N Engl J Med. 2013; 368: 699-708
        • Agnelli G.
        • Buller H.R.
        • Cohen A.
        • Curto M.
        • Gallus A.S.
        • Johnson M.
        • Masiukiewicz U.
        • Pak R.
        • Thompson J.
        • Raskob G.E.
        • Weitz J.I.
        Oral apixaban for the treatment of acute venous thromboembolism.
        N Engl J Med. 2013; 369: 799-808
        • Heidbuchel H.
        • Verhamme P.
        • Alings M.
        • Antz M.
        • Hacke W.
        • Oldgren J.
        • Sinnaeve P.
        • Camm A.J.
        • Kirchhof P.
        EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary.
        Eur Heart J. 2013; 34: 2094-2106
        • Hart R.G.
        • Eikelboom J.W.
        • Ingram A.J.
        • Herzog C.A.
        Anticoagulants in atrial fibrillation patients with chronic kidney disease.
        Nat Rev Nephrol. 2012; 8: 569-578
        • Harel Z.
        • Sholzberg M.
        • Shah P.S.
        • Pavenski K.
        • Harel S.
        • Wald R.
        • Bell C.M.
        • Perl J.
        Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD.
        J Am Soc Nephrol. 2014; 25: 431-442
        • Sardar P.
        • Chatterjee S.
        • Herzog E.
        • Nairooz R.
        • Mukherjee D.
        • Halperin J.L.
        Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials.
        Can J Cardiol. 2014; 30: 888-897
        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • Mulrow C.
        • Gøtzsche P.C.
        • Ioannidis J.P.A.
        • Clarke M.
        • Devereaux P.J.
        • Kleijnen J.
        • Moher D.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
        BMJ. 2009; 339: b2700
        • Turner R.M.
        • Bird S.M.
        • Higgins J.P.T.
        The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews.
        PloS One. 2013; 8: e59202
        • Pineo G.F.
        • Gallus A.S.
        • Raskob G.E.
        • Chen D.
        • Ramirez L.-M.
        • Ramacciotti E.
        • Lassen M.R.
        • Wang L.
        Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.
        J Thromb Haemost. 2013; 11: 444-451
        • Providência R.
        • Marijon E.
        • Boveda S.
        • Barra S.
        • Narayanan K.
        • Le Heuzey J.-Y.
        • Gersh B.J.
        • Gonçalves L.
        Meta-analysis of the Influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation.
        Am J Cardiol. 2014; 114: 646-653
        • McMahan D.A.
        • Smith D.M.
        • Carey M.A.
        • Zhou X.H.
        Risk of major hemorrhage for outpatients treated with warfarin.
        J Gen Intern Med. 1998; 13: 311-316
        • Olesen J.B.
        • Lip G.Y.H.
        • Kamper A.-L.
        • Hommel K.
        • Køber L.
        • Lane D.A.
        • Lindhardsen J.
        • Gislason G.H.
        • Torp-Pedersen C.
        Stroke and bleeding in atrial fibrillation with chronic kidney disease.
        N Engl J Med. 2012; 367: 625-635
        • Mani H.
        • Lindhoff-Last E.
        New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness.
        Drug Des Devel Ther. 2014; 8: 789-798
      1. FDA Approved Drug Products: Eliquis.
        2012 (Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf. Accessed on September 9, 2014.)
        • Michels W.M.
        • Grootendorst D.C.
        • Verduijn M.
        • Elliott E.G.
        • Dekker F.W.
        • Krediet R.T.
        Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size.
        Clin J Am Soc Nephrol. 2012. 2010; 5: 1003-1009